Clinical Trial Update: Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II multi-center study comparing perioperative Ivonescimab to Pembrolizumab plus standard of care in patients with resectable, locally advanced head and ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Fudan University | Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC | Phase 2 | Status: NOT_YET_RECRUITING